Epidemiology and Treatment Modalities for BPH Epidemiology and Treatment Modalities for BPH
A new review provides insight into the epidemiology of benign prostatic hyperplasia and explores the currently available treatment options for this condition.Translational Andrology and Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 10, 2020 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

Can pumpkin seed extract help relieve the symptoms of enlarged prostate?
(Natural News) Men who are suffering from a condition called benign prostatic hyperplasia (BPH) or enlarged prostate may find relief from their symptoms with the humble pumpkin seed, according to a study published in the Journal of Medicinal Food. European researchers investigated the effects of a supplement containing pumpkin seed extract on the symptoms of BPH.... (Source: NaturalNews.com)
Source: NaturalNews.com - October 21, 2019 Category: Consumer Health News Source Type: news

Alternatives to Surgery for an Enlarged Prostate
Up to 90 percent of men in their 70s have benign prostatic hyperplasia, or B.P.H., a nonmalignant growth of the prostate gland. (Source: NYT Health)
Source: NYT Health - August 26, 2019 Category: Consumer Health News Authors: Jane E. Brody Tags: Prostate Gland Men and Boys Bladder Urinary Tract Surgery and Surgeons Source Type: news

Corinth MedTech Appoints Steven Duddy as New President and CEO
CUPERTINO, Calif., Aug. 13, 2019 -- (Healthcare Sales & Marketing Network) -- Corinth MedTech, a medical device company and the developer of the Veloxion™ System for relieving the symptoms of BPH (Benign Prostatic Hyperplasia) and TURBT (Transurethral Res... Devices, Urology, Personnel Corinth MedTech, Veloxion, Benign Prostatic Hyperplasia, TURBT (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 13, 2019 Category: Pharmaceuticals Source Type: news

UCLA study links progenitor cells to age-related prostate growth
The prostates of older mice contain more luminal progenitor cells — cells capable of generating new prostate tissue — than the prostates of younger mice, UCLA researchers have discovered.The observation,published in  Cell Reports, helps explain why, as people age, the prostate tends to grow, leading to an increased risk for prostate cancer and other conditions.“Understanding what’s causing the prostate to grow with age helps us to consider strategies to prevent the expansion of these cells and possibly reduce a person’s risk for prostate growth or disease,” said Andrew Goldstein, me...
Source: UCLA Newsroom: Health Sciences - August 7, 2019 Category: Universities & Medical Training Source Type: news

Ghana: Lycopene and Prostate Cancer - Objective Review
[Ghanaian Times] In the Naturopathic Urological community, especially prostate health, two of the most popular ingredients are probably lycopene and saw palmetto. Saw palmetto is a plant whose berries are frequently used to help manage symptoms of an enlarged prostate (benign prostatic hyperplasia). (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 25, 2019 Category: African Health Source Type: news

Spotlight on Saw Palmetto
Saw palmetto (Serenoa repens) is a small palm tree native to the southeastern United States. Currently, saw palmetto is used as a dietary supplement for urinary symptoms associated with benign prostatic hyperplasia (BPH), as well as for chronic pelvic pain, decreased sex drive, migraine, hair loss, and other conditions.According to a 2017 systematic review of 22 studies, saw palmetto was one of the most frequently used herbal supplement. (Source: NCCAM Featured Content)
Source: NCCAM Featured Content - July 16, 2019 Category: Complementary Medicine Authors: NCCIH Source Type: news

Erectile Dysfunction Presents Large Global Health Burden
Condition is risk factor for benign prostatic hyperplasia, cardiovascular disease, dementia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 12, 2019 Category: Cancer & Oncology Tags: Cardiology, Endocrinology, Family Medicine, Geriatrics, Internal Medicine, Neurology, Oncology, Urology, Journal, Source Type: news

Large Real-World Study Backs up UroLift ’s Effectiveness
Teleflex Inc. received favorable results for a multi-center study reaffirming the safety and effectiveness of its UroLift System. The Wayne, PA-based company said the results were published in the Journal of Endourology. The multi-center, retrospective study examined the results of 1,413 consecutive patients who received the UroLift System for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The trial took place over the course of two years across 14 sites in North America and Australia. Data published from the study show that patients from multiple subgroups treated with the UroLift Sys...
Source: MDDI - July 9, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Medeon invests in ortho, urologic companies
Medeon Biodesign (TPEx:6499)  said today that it recently led and closed investments in an orthopedics startup and a company whose device was designed to treat benign prostatic hyperplasia (BPH). Panther Orthopedics is a Silicon Valley startup working on fixation solutions for orthopedic extremity applications. Prodeon is a Taiwan-based company offering a simple, office-based treatment option for BPH patients who are seeking immediate relief from lower urinary tract symptoms (LUTS). Panther Orthopedics’ FDA- 510(k) cleared Puma System is designed to treat orthopedic injuries with the benefits of screws and flexi...
Source: Mass Device - July 8, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Business/Financial News Funding Roundup News Well Orthopedics Urology Wall Street Beat Medeon Biodesign pantherorthopedics Prodeon Source Type: news

Benign Prostatic Hyperplasia (BPH) | Medscape Benign Prostatic Hyperplasia (BPH) | Medscape
Review in-depth clinical information, latest medical news, and guidelines on BPH (benign prostatic hyperplasia) including drug and non-drug BPH treatment and BPH surgery for benign prostatic hyperplasia or benign prostatic hypertrophy. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2019 Category: Consumer Health News Tags: Resource Center Source Type: news

Making Prostate Ablation Devices Safer
FDA has ramped up medical device safety efforts in several areas this year. Most recently, the agency has turned its attention to devices designed to ablate prostate tissue. The agency issued draft guidance Tuesday to provide recommendations for device manufacturers regarding the clinical testing that must be conducted in accordance with special controls for high-intensity ultrasound systems for prostate tissue ablation devices regulated under the agency’s 510(k) premarket notification program. This draft guidance also outlines recommended clinical data to support marketing submissions for pro...
Source: MDDI - June 25, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Regulatory and Compliance Source Type: news

#MayoClinicRadio podcast: 6/22/19
Listen: Mayo Clinic Radio 6/22/19 On the Mayo Clinic Radio podcast, Dr. Mitchell Humphreys, a Mayo Clinic urologist, highlights prostate health and treatment options for benign prostatic hyperplasia. Also on the program, Dr. Francisco Lopez-Jimenez, a Mayo Clinic cardiologist, discusses sex after a heart attack. And Dr. Bruce Levy, a Mayo Clinic orthopedic surgeon, shares how his patients' experiences [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 24, 2019 Category: Databases & Libraries Source Type: news

Aquablation Shows & quot;Promising & quot; Outcomes in BPH Patients With Large Prostates Aquablation Shows & quot;Promising & quot; Outcomes in BPH Patients With Large Prostates
Aquablation appears to effectively and safely treat benign prostatic hyperplasia (BPH) in prostates of up to 150 cc, an industry-funded study suggests.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - June 11, 2019 Category: Radiology Tags: Urology News Source Type: news

5-ARIs for Benign Prostatic Hyperplasia Can Lead to Delayed Prostate Cancer Diagnosis
Researchers looked at the use and effects of 5 α-reductase inhibitors to treat benign prostatic hyperplasia on prostate cancer outcomes. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

AUA: Marijuana Tied to Increased Risk for LUTS Medications in BPH
MONDAY, May 6, 2019 -- Marijuana use is associated with both sperm functional defects and an increased risk for being on a lower urinary tract symptom (LUTS) medication among men with benign prostatic hyperplasia (BPH)/LUTS, according to two studies... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 6, 2019 Category: Pharmaceuticals Source Type: news

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
(University of California - San Diego) University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 6, 2019 Category: Cancer & Oncology Source Type: news

Enucleation Might Be Better Option for Men With Benign Prostatic Hyperplasia Enucleation Might Be Better Option for Men With Benign Prostatic Hyperplasia
Enucleation might be a better option than resection of the prostate for men with benign prostatic hyperplasia (BPH), according to a new meta-analysis.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 1, 2019 Category: Surgery Tags: Urology News Source Type: news

Hydrocision, Procept BioRobotics ink licensing deal
Hydrocision said today that it inked an exclusive worldwide licensing deal to allow Procept BioRobotics to use its pump cartridge technology for urological applications. Through the agreement, Redwood Shores, Calif.-based Procept BioRobotics will gain the rights to use Boston-based Hydrocision’s pump cartridge technology in its AquaBeam robotic system designed to performed autonomous tissue removal for treating benign prostatic hyperplasia. “This global agreement with Procept BioRobotics is another significant and strategic step to bring the value of our differentiated technology into new surgical applications ...
Source: Mass Device - March 26, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News HydroCision Inc. Procept BioRobotics Source Type: news

Teleflex touts real-world UroLift study data
Teleflex (NYSE:TFX) today released results from real-world studies of its UroLift minimally invasive treatment for benign prostatic hyperplasia, touting its safety and effectiveness. Data from the studies were presented at the 2019 European Association of Urology meeting in Barcelona, Spain. The UroLift system uses tiny devices inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate, the Wayne, Penn.-based company said. Teleflex said that it presented data from a real-world retrospective study of 30 men with urinary rete...
Source: Mass Device - March 21, 2019 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Urology Teleflex Source Type: news

Lumenis Announces New Clinical Breakthroughs Using Its Patent-Protected MOSES(TM) Technology
Procedure time reduction in lithotripsy and benefits in BPH treatments YOKNEAM, Israel, March 15, 2019 -- (Healthcare Sales & Marketing Network) -- Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophtha... Devices, Urology Lumenis, lithotripsy, benign prostatic hyperplasia, MOSES (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 15, 2019 Category: Pharmaceuticals Source Type: news

NeoTract ’ s UroLift system gains expanded insurance coverage
Teleflex (NYSE:TFX) subsidiary NeoTract said that two more health insurers have agreed to offer coverage for the company’s UroLift system or patients with an enlarged prostate. The Wayne, Penn.-based subsidiary of Teleflex said that major U.S. insurer Humana and the Motion Picture Industry Pension & Health Plans (MPI), administered by Anthem Blue Cross, have added UroLift to its covered treatment systems. UroLift is a minimally invasive in-office treatment designed to provide rapid relief and recovery from the symptoms of benign prostatic hyperplasia (BPH). “These coverage decisions are a maj...
Source: Mass Device - February 15, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Business/Financial News Featured Implants News Well Urology Anthem Blue Cross Blue Shield Humana NeoTract Teleflex Source Type: news

Boston Sci ’s BPH Treatment Effective in Preserving Sexual Function After 4 Years
Boston Scientific revealed promising 4-year-data from a post-market clinical trial evaluating the Rezūm Water Vapor Therapy in the treatment of benign prostatic hyperplasia (BPH). Results from the Marlborough, MA-based company’s trial show the device provides sexual function four years after the treatment. The clinical trial results showed a surgical retreatment rate of 4.4% and no new adverse events noted between years three and four. The clinical results also highlighted continued preservation of sexual function, including no de novo erectile dysfunction reported at four years. The results ...
Source: MDDI - January 28, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Boston Scientific touts 4-year Rez ūm BPH treatment trial data
Boston Scientific (NYSE:BSX) last Friday released results from a clinical trial of its Rezūm benign prostatic hyperplasia device, touting durable results and the preservation of sexual function at four years post-treatment. Results from the trial are set to be published in the journal Urology, and have already been published online, the Marlborough, Mass.-based company said. “This four-year study supports the use of the first-of-its-kind Rezūm System as a minimally invasive alternative for men with moderate-to-severe BPH who do not want to rely on pharmaceutical management of their symptoms. The data demonstra...
Source: Mass Device - January 28, 2019 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Featured Urology Boston Scientific Source Type: news

New Four-Year Data Demonstrate Rezand#363;m(TM) Water Vapor Therapy Offers Significant Durable Improvement of Benign Prostatic Hyperplasia Symptoms
MARLBOROUGH, Mass., Jan. 25, 2019 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (NYSE: BSX) today announced that data from a randomized clinical trial demonstrate that Rezūm™ Water Vapor Therapy, a minimally invasive trea... Devices, Urology Boston Scientific, Water Vapor Therapy, benign prostatic hyperplasia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 25, 2019 Category: Pharmaceuticals Source Type: news

LUTS/BPH Decision Aid Improves Treatment-Decision Quality LUTS/BPH Decision Aid Improves Treatment-Decision Quality
A decision aid for men with lower-urinary-tract symptoms due to benign prostatic hyperplasia (LUTS/BPH) can help them to make better informed, more value-congruent treatment decisions, new research shows.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 23, 2019 Category: Consumer Health News Tags: Urology News Source Type: news

Endoscopic Transvesical Adenomectomy Allows Less-Invasive Treatment of Large BPH Endoscopic Transvesical Adenomectomy Allows Less-Invasive Treatment of Large BPH
Endoscopic transvesical adenomectomy of the prostate (ETAP) provides a less-invasive alternative for treating large benign prostatic hyperplasia (BPH), researchers from the Netherlands report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 17, 2019 Category: Consumer Health News Tags: Urology News Source Type: news

One size does not fit all in benign prostatic hyperplasia treatment
Benign prostatic hyperplasia, or BPH, is a common problem for older men. This condition also is known as an enlarged prostate. With benign prostatic hyperplasia, the prostate enlarges, and the gland presses against, and pinches, the urethra. And the bladder wall becomes thicker. An enlarged prostate gland can cause uncomfortable urinary symptoms, including slowing or [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - November 8, 2018 Category: Databases & Libraries Source Type: news

Teleflex ’ s NeoTract wins Japanese approval for UroLift BPH treatment system
Teleflex (NYSE:TFX) subsidiary NeoTract said today it won Shonin approval from Japan’s Ministry of Health, Labor and Welfare for its Urolift system intended for treating benign prostatic hyperplasia. The UroLift system uses tiny devices inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate, the Pleasanton, Calif.-based company said. NeoTract said that it estimates there are approximately 2.3 million men age 50 and older in Japan who have been diagnosed with BPH. The company said that now that it has rec...
Source: Mass Device - November 5, 2018 Category: Medical Devices Authors: Fink Densford Tags: Featured Regulatory/Compliance Urology NeoTract Source Type: news

The Japanese rush can be used to prevent and treat the enlargement of the prostate
(Natural News) Talk about medicinal plants, and the first thing that people imagine is a shrub in the middle of nowhere. However, a study in BMC Complementary and Alternative Medicine found that the Japanese rush, a common plant seen in gardens around the world, could be used to treat benign prostatic hyperplasia (BPH), a noncancerous enlargement of... (Source: NaturalNews.com)
Source: NaturalNews.com - November 5, 2018 Category: Consumer Health News Source Type: news

Expect Boston Scientific to Keep Rounding Out Its Portfolio with M & amp;A
 Boston Scientific has been on quite the shopping spree in 2018. The Marlborough, MA-based company has announced eight acquisitions since the beginning of the year, plus a hefty investment in Millipede, which is likely to lead to an acquisition within the next year or so. Naturally, the company's aggressive M&A strategy has attracted attention from industry analysts who are eager to see if this spree will continue in 2019. During the company's third-quarter earnings call on Thursday, CFO Daniel Brennan said Boston Scientific still has a "tremendous amount" of financial flexibility. Loo...
Source: MDDI - October 25, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Teleflex ’ s NeuroTract touts UK Urolift decision
Teleflex (NYSE:TFX) subsidiary NeoTract said today that the UK Government selected the UroLift system, intended to treat patients with benign prostatic hyperplasia, as one of seven Accelerated Access Collaborative “Rapid Uptake Products.” The Wayne, Penn.-based company said that the system will now receive support from the Accelerated Access Collaborative which will increase its use by the UK’s NHS. The decision to include the device in the list follows its placement last year by NHS England as a recipient of the Innovation and Technology Tariff, which also helped support uptake of the trea...
Source: Mass Device - October 24, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Urology Teleflex Source Type: news

Steam treatment for BPH: Mayo Clinic Radio Health Minute
It's a common problem for older men?? benign prostatic hyperplasia, or BPH. "BPH is a fancy way of saying the prostate is getting larger, and we don't want it to," says Dr. Toby Kohler, a Mayo Clinic urologist. In this Mayo Clinic Radio Health Minute, Dr. Kohler describes a new approach for treatment of BPH. [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 17, 2018 Category: Databases & Libraries Source Type: news

Boston Scientific & #039;s Aggressive M & amp;A Strategy Continues with Augmenix Deal
Tuck-in acquisitions continue to play a key role in Boston Scientific's strategy this year, as evidenced by the company's latest deal, which also happens to be its largest so far in 2018.  The Marlborough, MA-based company has agreed to pay $500 million upfront and up to $100 million for sales-based milestones to acquire Augmenix. This private company is based in Bedford, MA and has developed a product called SpaceOAR, which intended to reduce common and debilitating side effects for men who undergo prostate cancer radiotherapy. Not only is Augmenix the eighth acquisition Boston Scientific has reported this yea...
Source: MDDI - September 7, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Boston Scientific puts up $600m for Augmenix
Boston Scientific (NYSE:BSX) said yesterday that it put $600 million on the table for Augmenix and its SpaceOar device. The deal for Bedford, Mass.-based Augmenix calls for $500 million in up-front cash and another $100 million pegged to sales-based milestones, Boston said. The SpaceOar hydrogel device, which won CE Mark approval in the European Union in 2010 and 510(k) clearance from the FDA in April 2015 , is designed to separate the prostate from the rectal wall during radiation treatment for prostate cancer. The product is delivered through a small needle as a liquid, which then solidifies into a so...
Source: Mass Device - September 7, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Urology Wall Street Beat Augmenix Inc. Boston Scientific Source Type: news

Surgery-First Strategy Cost-Effective in Benign Prostatic Hyperplasia Surgery-First Strategy Cost-Effective in Benign Prostatic Hyperplasia
Using surgery as an initial treatment for moderate-to-severe benign prostatic hyperplasia (BPH) is more economically attractive than upfront pharmacotherapy followed by surgery for those who fail, researchers from Canada report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 30, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Study examines relationship between social disparities and benign prostatic hyperplasia
(Wiley) In an Andrologia study of 100,000 men in Korea, social disparities -- such as low education level and low household income, current or previous use of medical aid health insurance, blue-collar employment or unemployment, divorce, and low social capital of communities -- were all linked with a higher prevalence of benign prostatic hyperplasia (BPH), a condition that is characterized by an enlarged prostate due to aging, lower urinary tract blockage, and other factors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 22, 2018 Category: International Medicine & Public Health Source Type: news

Aquablation May Improve Symptoms in Men With Large Prostates Aquablation May Improve Symptoms in Men With Large Prostates
Aquablation, which uses robotically guided waterjets to remove excess prostate tissue, appears to improve lower-urinary-tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH) and large prostate glands, researchers report.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 14, 2018 Category: Surgery Tags: Urology News Source Type: news

OmniGuide to buy German urological laser-maker
OmniGuide (Cambridge, Mass.) plans to acquire Lisa Laser Products, a surgical laser company based in Katlenburg-Lindau, Germany. Terms were not disclosed. Lisa Laser’s product portfolio consists of laser hardware units, laser fibers, endoscopes and other accessories for laser-assisted surgery. The company has been developing surgical laser technologies consisting of both thulium and holmium lasers for the treatment of benign prostatic hyperplasia, since 1989. More than half of men in the United States will develop the condition by age 60, and 30 million already have it, according to the American Urological ...
Source: Mass Device - August 6, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Business/Financial News Urology lisalaser OmniGuide Source Type: news

Medical News Today: What are the treatment options for BPH?
Benign prostatic hyperplasia, or BPH, is the medical term for an enlarged prostate. BPH can cause difficulties with urination. Treatment options for BPH include watchful waiting, medication, minimally invasive procedures, and surgery. Lifestyle changes can also help improve a person ’s symptoms. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 12, 2018 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news

New treatment option available for men suffering from benign prostatic hyperplasia
(University of California - San Diego) Physicians at UC San Diego Health are now offering prostate artery embolization as a new treatment option for men with benign prostatic hyperplasia, or an enlarged prostate. The minimally invasive procedure is an alternative to surgery, with no hospital stay, little operative pain and lower cost. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 9, 2018 Category: Cancer & Oncology Source Type: news

Zydus Cadila gets USFDA nod for prostate condition treatment drug
The drug is used to treat symptoms of Benign Prostatic Hyperplasia (BPH) -- also called prostate gland enlargement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 25, 2018 Category: Pharmaceuticals Source Type: news

Medical News Today: Can saw palmetto reduce enlarged prostate?
Saw palmetto is an herbal remedy with many potential uses in healthcare. One such use is the treatment of benign prostate hyperplasia (BPH). Although a popular remedy, research into the herb ’s efficacy is still ongoing and the results to date are inconclusive. Here, we look at the other treatments also available. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 24, 2018 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news

Medical News Today: Can BPH cause kidney failure?
Benign prostatic hyperplasia (BPH) refers to enlargement of the prostate that is unrelated to cancer. Because of the positions of the prostate and kidneys, an enlarged prostate can cause kidney, or renal, failure. Knowing the symptoms can ensure quick treatment. Learn about the links between renal failure and BPH here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 23, 2018 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news

Medical News Today: Is green tea good for BPH?
There are many potential treatments for an enlarged prostate or benign prostatic hyperplasia (BPH). Many people look to green tea to manage their BPH, and the science suggests that it may offer relief for some symptoms, and provide other health benefits. Learn more about green tea for BPH, and whether it works, here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 23, 2018 Category: Consumer Health News Tags: Nutrition / Diet Source Type: news

Procept BioRobotics touts early results from AquaBeam BPH waterjet ablation trial
Procept BioRobotics today released early results from a study of its AquaBeam waterjet ablation therapy system designed for the endoscopic resection of prostate tissue exploring its use in treating benign prostatic hyperplasia, touting that it already met its primary safety and efficacy endpoints. Results were presented at the American Urological Association’s annual meeting in San Francisco by study co-principal investigator Dr. Mihir Desai of the Keck School of Medicine of USC, the Redwood Shores, Calif.-based company said. The AquaBeam system uses a robotically controlled waterjet to ablate prostate tissue wi...
Source: Mass Device - May 21, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Robotics Urology Procept BioRobotics Source Type: news

Teleflex ’ s NeoTract wins AUA support for UroLift system as standard-of-care
Teleflex (NYSE:TFX) subsidiary NeoTract said today that the American Urological Association now recommends the use of NeoTract’s UroLift system as a standard of care treatment for lower urinary tract symptoms due to benign prostatic hyperplasia. The company’s UroLift system uses tiny devices inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate, the Pleasanton, Calif.-based company said. In a set of newly released clinical guidelines, the AUA recommends that the UroLift prostatic urethral lift pro...
Source: Mass Device - May 18, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Urology NeoTract Teleflex Source Type: news

Mayo Clinic Q and A: New steam treatment for benign prostatic hyperplasia
DEAR MAYO CLINIC: I was diagnosed with benign prostatic hyperplasia four years ago. It didn?t bother me at first, so my health care provider recommended watchful waiting. But now it?s causing quite a few problems, and we?re talking about surgery. I heard there?s a new treatment for benign prostatic hyperplasia that involves steam. Does it [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 8, 2018 Category: Databases & Libraries Source Type: news

Boston Scientific Closes NxThera Acquisition
MARLBOROUGH, Mass., April 30, 2018 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of NxThera. The company developed the Rezūm® system, a minimally invasive thera... Devices, Urology, Mergers & Acquisitions Boston Scientific, NxThera, Rezum system, benign prostatic hyperplasia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 30, 2018 Category: Pharmaceuticals Source Type: news

Boston Scientific closes $400m NxThera buy
Boston Scientific (NYSE:BSX) said today that closed the $406 million acquisition of NxThera and its Rezūm benign prostatic hyperplasia device, which uses steam to ablate excess prostate tissue. The deal called for $306 million in up-front cash from Marlborough, Mass.-based Boston Scientific, with another $100 million in potential milestones over the next four years. Boston, which in December 2015 led a $40 million funding round for NxThera, said the existing investment means it will have to put $240 million down and another $85 million on the table in milestones. NxThera is based in ...
Source: Mass Device - April 30, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Urology Wall Street Beat Boston Scientific NxThera Inc. Source Type: news